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Abstract   26 
Purpose: Resistance to bevacizumab (BEV) in glioblastoma (GBM) is believed to occur 27 
via activation of molecular networks including the mTOR/PI3K pathway.  Implementing an 28 
MRI/PET molecular imaging biomarker approach, we sought to interrogate response to 29 
combining BEV with the mTOR/PI3K inhibitor BEZ235. Methods: Tumors were 30 
established by orthotopically implanting U87MG-luc2 in mice. Animals were treated with 31 
BEZ235 and/or BEV, and imaged using diffusion weighted-MRI, T2 weighted (T2w), and 32 
T2* weighted (T2*w) before and following delivery of superparamagnetic iron oxide 33 
(SPIO) contrast. Maps for changes in relaxation rates: ΔR2, ΔR2* and apparent diffusion 34 
coefficient (ADC) were calculated. Vessel Size Index (VSI) and micro vessel density index 35 
(MDI) were derived.  3´-deoxy-3´-[18F]fluorothymidine ([18F]FLT)- and O-(2-36 
[18F]fluoroethyl)-L-tyrosine ([18F]FET) PET was further performed and tumor 37 
endothelium/proliferation markers assessed by immunohistochemistry. Results: Treatment 38 
with BEV resulted in a pronounced decrease in tumor volume (T2w MRI). No additive 39 
effect on tumour volume was observed in BEV/BEZ235 combination compared with BEV 40 
monotherapy. Ki67 proliferation index staining and [18F]FLT uptake studies were used to 41 
support observations. Using ΔR2* and ΔR2 values respectively, BEZ235 + BEV 42 
combination significantly reduced tumor microvessel volume in comparison to BEV alone. 43 
Decreased MDI was further observed in the combination group; supported by von 44 
Willebrand Factor (vWF) immunohistochemistry. We observed decreased [18F]FET uptake 45 
following BEV, but failed to observe further reduced [18F]FET uptake in the combination 46 
cohort. vWF IHC analysis  showed mean tumor vessel size increased in all cohorts. 47 
Conclusions: Assessing MR imaging biomarker parameters together with [18F]FET and 48 
[18F]FLT PET, informed drug combination mechanism of action and provided clues  as to 49 
potential clinical response. Translation of a BEZ35/BEV combination regimen could 50 
support reduction of peritumoral edema obviating the requirement for steroids. 51 
Implementing hypothesis driven molecular imaging studies facilitates the interrogation of 52 
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drug response in the pre-clinic. These data may more accurately predict the clinical 53 
potential of novel therapeutic approaches in oncology. 54 
 55 
Keywords: Glioblastoma, bevacizumab, BEZ235, T2w-MRI, PET  56 
57 
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Introduction 58 
GBM is the most common primary adult brain tumor. Treatment remains a challenge with 59 
median overall survival just 14.6 months [1]. GBMs are highly vascularized, ostensibly 60 
representing an attractive target for anti-angiogenic therapies.  Clinical trials with BEV, a 61 
monoclonal antibody against vascular endothelial growth factor (VEGF) in recurrent GBM, 62 
have shown benefit in response rate (28 % - 35 %) and 6 month progression free survival 63 
(29 % - 43 %) [2]. Nevertheless, BEV does not improve overall survival, nor does it 64 
improve survival when delivered in conjunction with the “Stupp” protocol [3].  Tumor 65 
relapse occurs in the majority of patients, characterized by local and distant infiltration [4]. 66 
Moreover, in a limited number of reports BEV has been shown to enhance GBM invasion 67 
[5], which may be facilitated via upregulation of several pathways. Most recently, the MET 68 
pathway has been implicated [6]. However, previous work has further suggested a role for 69 
BEV-enhanced invasion via PI3K AKT signaling [7]. Moreover, several studies suggest 70 
that the EGFR/PTEN/Akt/mTOR signaling pathway is activated in many cancers including 71 
GBM. In this pathway, amplification of the gene encoding the EGFR occurs commonly in 72 
GBM, leading to activation of downstream kinases including PI3K, Akt, and mTOR with 73 
EGFR overexpression occurring in c.60 % of primary GBMs [8]. PI3K, AKT and mTOR, 74 
an effector of PI3K, control several cellular functions critical for tumorigenesis, including 75 
proliferation, apoptosis and motility [9]. Thus, we hypothesized that treatment with a 76 
PI3K/AKT/mTOR inhibitor might work synergistically with BEV to improve outcomes 77 
(tumor growth, volume, survival) in the GBM pre-clinical setting. Novartis 78 
Pharmaceuticals have developed BEZ235, an imidazo[4,5-c]quinoline derivative and dual 79 
PI3K/mTOR inhibitor currently under investigation for the treatment of solid tumours [10].  80 
BEZ235 inhibits VEGF secretion in vitro [9]. The anti-tumor activity of BEZ235, in 81 
combination with the VEGF inhibitor sorafenib was shown as superior to BEZ235 or 82 
sorafenib alone in a renal cell carcinoma study [11].  83 
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Herein we sought to assess the effect of combining BEZ235+BEV in a pre-clinical GBM 84 
model. Moreover, as an ongoing challenge exists to accurately monitor patients’ response 85 
to BEV, we further sought to investigate novel imaging biomarkers towards mechanistic 86 
interrogation of treatment. As recently described [12], ADC, T2 and T2* mapping 87 
following delivery of SPIO contrast were implemented to assess blood volume, vessel 88 
density and vessel size.  [18F]FET PET was implemented to assess vessel amino acid 89 
transport and [18F]FLT PET to monitor cell proliferation. Thus, the following in vivo 90 
response biomarkers were assessed: (1) tumor volume as estimated by T2w MRI (2) tumor 91 
vessel density and size assessed using T2 and T2* MRI following delivery of SPIO 92 
contrast, and (3) tumor cell proliferation assessed using FLT and FET-PET. 93 
 94 
Material & Methods 95 
Tissue Culture  96 
Authenticated U87MG-luc2 cells were obtained from Caliper Life Science (A PerkinElmer 97 
Company, Hopkinton, MA, USA).  Cells were cultured in Eagle’s Minimum Essential 98 
Medium (EMEM) (Gibco, Invitrogen, Carlsbad, CA, USA) supplemented with 10 % heat-99 
inactivated fetal bovine serum (FBS), 1 % L-glutamine (2 mM), 1 % 100 
penicillin/streptomycin (50 units/ml), all from Sigma-Aldrich (St. Louis, MO, USA).  Note:  101 
 102 
Animal Experiments 103 
All experiments were in accordance with the German Law on the Care and Use of 104 
Laboratory Animals and approved by the Landesamt für Natur, Umwelt und 105 
Verbraucherschutz Nordrhein-Westfalen (LANUV). GBM cells were stereotactically 106 
implanted into the right striatum of female NMRI (Charles River) nude mice.  Animals 107 
were anaesthetized with Ketamine/Xylazine (20 mg/kg each) and placed in a stereotactic 108 
frame.  A midline incision was made, and a burr hole drilled in the skull. 1.0 x 105 U87MG-109 
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luc2 cells in 2 µl of plain DMEM were injected with a 10 µl Hamilton syringe at the 110 
following coordinates: lateral -2.0 mm, dorsoventral -2.5 mm, using the bregma as a 111 
reference. Bioluminescence imaging of luciferase positive cells was initially used as a 112 
surrogate marker of tumour growth when establishing the orthotopic model and defining 113 
tumour growth kinetics. 114 
 115 
Imaging and Treatment Protocols 116 
Animals were imaged at baseline, at 3 weeks (immediately prior to treatment) and at week 117 
6. Treatment time-points were selected based on U87-luc orthotopic growth kinetics   118 
established prior to commencing the current study using Bioluminescence Imaging as a 119 
surrogate marker of tumour growth. Specifically, animals were imaged using 3´-deoxy-3´-120 
[18F]fluorothymidine ([18F]FLT)- and O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET)- PET 121 
and MRI (diffusion weighted-MRI, T2w and T2*w before and following delivery of SPIO 122 
contrast).  Mice were randomized into four groups: Control (vehicle), BEZ235 alone (45 123 
mg/kg po, daily 5/7, 2/7 off), BEV alone (10 mg/kg ip, alternate days 12/7), and 124 
Combination (45 mg/kg po, daily 5/7, 2/7 off; 10 mg/kg ip, alternate days 12/7) (n=7 125 
animals per group).  Post-treatment imaging was performed at week 6. 126 
 127 
MRI   128 
Experiments were performed on a 9.4 T small animal scanner with 20 cm bore size with a 129 
mouse brain surface coil (Bio-Spec 94/20; Bruker BioSpin MRI GmbH, Germany).  The 130 
system was operated with ParaVision 5.1 software (Bruker BioSpin MRI GmbH, 131 
Germany). Mice were anaesthetized with isoflurane (5 % induction, 1-1.5 % maintenance, 132 
DeltaSelect; Dreieich, Germany) in compressed air/O2 (70:30, 1 L/min).  Body temperature 133 
and respiration rate were continuously monitored.  An i.v. catheter (27 G) was introduced 134 
into one tail vein. The animal was placed prone in the animal cradle with the head fixed by 135 
bite bar, nose cone and earplugs.  We obtained T2w anatomical images with a fast spin echo 136 
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sequence in the sagittal, axial, and coronal imaging plane: TR = 2000 ms, TE = 50 ms, 137 
Rapid Acquisition with Relaxation Enhancement (RARE) factor 8, 8 averages (coronal 12), 138 
field of view 1.6 cm, matrix 128 x 128 (coronal 192), slice thickness 0.75 mm, resolution 139 
125 x 125 (coronal 83 µm²).  Tumor blood volume, tumor microvessel volume, tumor 140 
microvessel density and tumor vessel size, were determined by acquiring ADC maps and 141 
ΔT2 and ΔT2* maps before and after i.v. injection of very small superparamagnetic iron 142 
oxide particles (VSOP, C184, Ferropharm, Teltow, Germany 30 mg Fe/kg). C184 is coated 143 
with citrate and has a sphere size of 8 nm and a core size of 4 nm.  Protocol parameters 144 
were adapted as previously described [12, 13]. Multi Slice Multi Echo (MSME) spin echo 145 
sequence images for T2 mapping and multiple gradient echo (MGE) gradient echo 146 
sequence MR images for T2* mapping were obtained with the same geometry (FOV 16 147 
mm², matrix 64², slice thickness 0.3 mm). MSME was acquired with Repetition Time (TR) 148 
= 5000 ms and 10 echoes, Echo Time (TE) = 10.9, 21.8, 32.7, 43.6, 54.5, 65.4, 76.3, 87.2, 149 
98.1, 109 ms. MGE was acquired with TR = 1400 ms and 10 echoes, TE = 4, 8, 12, 16, 20, 150 
24, 28, 32 ms with a 60° hermite pulse.  Post contrast image acquisition was delayed by 3 151 
min. Data for an apparent diffusion coefficient (ADC) map with the same geometry were 152 
additionally acquired before contrast agent application, with a diffusion-weighted Echo 153 
Planar Imaging (EPI) protocol (TR/TE 7500/18.4 ms) with b = 0, 300, 800 s/mm2. Total 154 
scan time was approximately 45 minutes per animal. 155 
 156 
PET 157 
Mice were anaesthetized with isoflurane (4 % induction, 2 % maintenance DeltaSelect; 158 
Dreieich, Germany) in O2, and one lateral tail vein catheter was positioned using a 27 G 159 
needle connected to a 15 cm polyethylene catheter tubing. Twelve MBq of 3´-deoxy-3´-160 
[18F]fluorothymidine ([18F]FLT) or O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) were 161 
injected as a bolus (100 μl of [18F]FLT /[18F]FET solution flushed with 100 μl saline) via 162 
the tail vein, and subsequent PET scanning was performed. PET tracer specific 163 
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radioactivity obtained with the synthesis module employed was 30-70 GBq/µmol [18F-]FET 164 
was used to image amino acid transport, and [18F]FLT was used to image actively 165 
proliferating cells.  PET experiments were carried out using a high resolution (spatial 166 
resolution of 0.7 mm using iterative EM reconstruction including resolution recovery) 167 
small animal scanner (32 module quadHIDAC, Oxford Positron Systems Ltd., Oxford, UK) 168 
with uniform spatial resolution (< 1 mm) over a large cylindrical field (165 mm diameter, 169 
280 mm axial length) [14].  List-mode data were acquired for 20 min starting 70 min after 170 
tracer injection. 171 
 172 
Data Analysis 173 
PET data were reconstructed into a static frame using an iterative reconstruction algorithm. 174 
PET and MR images were co-registered using contours of the skull and head of the mice 175 
using the software VINCI (http://www.nf.mpg.de/vinci3/) [15].  T2w anatomical MR 176 
images were used to delineate the contour of the tumors, to measure their volumes, and to 177 
draw the volume-of-interest (VOI).   PET images were used to determine radiotracer uptake 178 
in the tumor.  To calculate tumor-to-background uptake ratios ([18F]FLT and [18F]FET T/B), 179 
the tumor [18F]FLT and [18F]FET uptake was divided by the radiotracer uptake in the mirror 180 
region of the tumors drawn in the contralateral hemisphere. For MRI data analysis, a 181 
Matlab routine (R2010b) was implemented for calculation of ΔR2, ΔR2* and ADC maps. 182 
ROI analysis was performed on the slice with the greatest tumor diameter. Vessel 183 
parameters, Vessel Size Index (VSI) and micro vessel density index (MDI) were derived as 184 
described previously [12].  The ADC map was calculated from diffusion-weighted images 185 
with a mono-exponential fit of the signal intensities of the diffusion-weighted images (b = 186 
0, 300, 800 s/mm²). R2* maps were calculated with the second echo (8 ms) by: 187 
 188 
∆𝑅2
∗ =  
2
3
 𝛿𝜔𝜉0 =  
ln (
𝐺𝐸𝑝𝑟𝑒
𝐺𝐸𝑝𝑜𝑠𝑡
)
𝑇𝐸
 189 
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       (1) 190 
R2 maps were determined with the third echo (32.7 ms) by: 191 
Δ𝑅2 = 0.694𝛿𝜔
2 3⁄ 𝜉0#
2 3⁄ 𝐴𝐷𝐶1 3⁄ 𝑅−2 3⁄ =
ln(
𝑆𝐸𝑝𝑟𝑒
𝑆𝐸𝑝𝑜𝑠𝑡
)
𝑇𝐸
  192 
(2) 193 
(ξ0 = blood volume fraction; δω = 2π B0 = frequency shift, # = number of 180° pulses; R194 
= Vessel Size Index (VSI) Δ = 1x10-3 = changes in the susceptibility, B0 = magnitude of 195 
the magnetic field). 196 
 197 
NB: ADC maps were acquired before contrast to facilitate subsequent calculation of vessel 198 
parameters, taking into account confounding effects of heterogeneous tumor diffusion [12]. 199 
Micro vessel density index was calculated from: 200 
 201 
𝑀𝐷𝐼 = 1.327#2
(
∆𝑅2
(∆𝑅2
∗)
2
3⁄
)
3
𝐴𝐷𝐶
 202 
   (3) 203 
 204 
Vessel size index (VSI) was calculated from: 205 
𝑉𝑆𝐼 = 0.425# (
𝐴𝐷𝐶
𝛿𝜔
)
1
2
(
∆𝑅2
∗
∆𝑅2
)
3
2
 206 
Median indices of tumor tissue within the skull were compared between groups. 207 
 208 
Immunohistochemistry (IHC) 209 
At week 6 (post treatment), tumors were excised, fixed in 4 % paraformaldehyde, 210 
embedded in paraffin and cut in 5 µm sections.  Following rehydration and heat-induced 211 
epitope retrieval for 30 min in citrate buffer (pH 6.0), sections were incubated in peroxidase 212 
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blocking solution (S3022; DAKO, Germany) for 5 min and treated with serum-blocking 213 
solution for 15 min.  Sections were incubated overnight at 4 °C with the rabbit anti-human 214 
primary antibodies against the proliferation marker Ki67  (dilution 1:100, ab16667, Abcam) 215 
and endothelial marker Von Willebrand factor (vWF, dilution 1:500, DAKO).  Labeling of 216 
the primary antibody was performed using a commercial avidin-biotin complex detection 217 
kit based on a biotinylated anti-rabbit antibody (goat anti-rabbit dilution 1:500, B21078, 218 
Invitrogen) according to the manufacturers manual, followed by incubation with 3,3'-219 
diaminobenzidine (DAB, D-5637; Sigma) for 5 min.  Sections were counterstained with 220 
hematoxylin, dehydrated and mounted using Entellan (Merck, Germany).  Ki67-positive 221 
cell number and total number of cells per image were quantified manually using cell 222 
counter in ImageJ software. Proliferation index was expressed as a percentage of Ki-67-223 
positive cells.  Microvessel density was determined using ImageJ software using a grid 224 
over lay method.  The number of positively stained vessels that crossed the overlaid grid-225 
lines were counted.  Vessel size was quantified using Image J with the Analyze Particles 226 
plugin.   227 
 228 
Statistical Analysis 229 
Statistical analyses were performed using GraphPad (San Diego, CA, USA) and SAS 230 
(Cary, NC, USA).  Data are represented as median ± standard deviation, unless otherwise 231 
stated. Two sample non-parametric median tests were employed as well as Pearson’s 232 
correlation test, using SigmaStat 3.0 (SPSS, Inc., Chicago, IL, USA).  P values < 0.05 were 233 
considered to be statistically significant.  A summary of statistical methods is included as 234 
supplementary material.   235 
 236 
Results 237 
Combined treatment with BEV + BEZ235 does not significantly enhance BEV tumor 238 
volume inhibitory effect 239 
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A significant decrease in tumor volume (T2w MRI) was observed 3 weeks following 240 
treatment in BEV treated tumors (94% reduction) and in combination treated tumors (97% 241 
reduction) (P < 0.05)  (Figure 1A). [Note: more than one tumor was observed in some 242 
animals. A summary of observations is provided (Supplementary Table 1) Thus, where 243 
possible, tumors were analyzed separately]. Animals treated with BEZ235 + BEV did not 244 
exhibit significantly reduced tumor volume in comparison with animals treated with BEV 245 
alone. No significant difference in [18F]FLT uptake was observed when BEV alone and 246 
BEV +BEZ235 treated cohorts were compared supporting MRI data (Figure 1B and C). 247 
[Note: untreated animals did not survive until the post treatment PET imaging session.] 248 
Ki67 staining further indicated that combined BEV/BEZ235 treatment did not reduce tumor 249 
proliferation compared to BEV alone. We observed a significant correlation with tumor cell 250 
proliferation measured with [18F]FLT PET and Ki67 staining (Supplementary Figure 1D).   251 
 252 
Combined treatment with BEV + BEZ235 causes decreased total tumor and micro-vessel 253 
blood volume compared to BEV alone  254 
A significant (47 %) decrease in total tumor blood volume was evident in animals treated 255 
with BEV in comparison to untreated animals (P < 0.05) (Figure 2A & B). Treatment with 256 
combination BEZ235/BEV resulted in a further decreased (51 %) total tumor blood volume 257 
when compared with animals treated with BEV alone (P < 0.05). Treatment with BEZ235 258 
or BEV alone did not alter tumor micro-vessel blood volume (Figure 2A and C).   259 
Treatment with combination BEZ235 and BEV caused a significant (57 %) reduction in 260 
tumor microvessel blood volume when compared with animals treated with BEV alone (P < 261 
0.01).   262 
 263 
Combined treatment effects of BEV + BEZ235 on tumor vessel density (MDI), size (VSI), 264 
vWF staining and [18F]FET uptake   265 
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Tumor vessel density (MDI) was significantly (69 %) reduced in animals treated with BEV 266 
alone in comparison with BEZ235 (Figure 3 A and B) (P < 0.05).  However, tumor vessel 267 
density was not reduced further in animals treated with combination BEZ235/BEV when 268 
compared with animals treated with BEV alone.  We observed a 46 % decrease in [18F]FET 269 
uptake in animals treated with BEV alone (non-significant) or in combination with BEZ235 270 
(49 % decrease, P < 0.05) when compared with animals treated with BEZ235 alone (Figure 271 
3 C and D).  No significant difference in [18F]FET uptake was observed when BEV alone 272 
and BEV + BEZ235 treated cohorts were compared. vWF staining showed a significant 273 
MVD decrease  in animals treated with BEZ235 + BEV in comparison with animals treated 274 
with BEV alone (Figure 3E). We compared MDI with vWF immuno-staining and found a 275 
significant correlation between both readouts irrespective of treatment group 276 
(Supplementary Figure 1A).  [18F]FET uptake also significantly correlated with MDI 277 
(Supplementary Figure 1B) and vWF staining irrespective of treatment group 278 
(Supplementary Figure 1C). Vessel size was assessed using T2* mapping after SPIO 279 
contrast. No effect on tumor vessel size was observed in any treatment cohort (Figure 4 A 280 
and B).   However, using vWF staining we observed that treatment with BEV alone or in 281 
combination with BEZ235 significantly increased tumor vessel size (Figure 4C and D). 282 
 283 
Discussion   284 
Common alterations in cell signaling networks occur in most GBMs including the 285 
PI3K/AKT and MEK/MAPK pathways [16].  These alterations drive GBM hallmarks 286 
including invasiveness, proliferation, survival and angiogenesis. Molecular diversity and 287 
reliance on multiple signaling pathways may explain why single-agent trials with 288 
molecularly targeted therapies have largely failed to demonstrate survival benefit in patient 289 
populations [17].  Herein, we have implemented a mechanistic hypothesis-driven multi-290 
modality imaging approach to study the effects of dual targeting VEGF and PI3K/mTOR in 291 
an orthotopic model.  292 
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BEV treatment has been shown to induce normalization of the blood brain barrier, and as a 293 
result, to reduce MR contrast enhancement due to a reduction in vessel permeability and 294 
perfusion. Nevertheless, while contrast enhancement does not accurately reflect tumor 295 
volume or vascular density, DCE-derived parameters may be used as efficient noninvasive 296 
biomarkers of response to anti-angiogenic therapies [18]. Indeed, the reference imaging 297 
method for non-invasive in vivo assessment of anti-angiogenic therapies is Dynamic 298 
Contrast-Enhanced MRI (DCE-MRI) [18-21], which provides information on tumour blood 299 
volume, extravascular/extracellular space fractions, blood-to-tissue transfer constant and 300 
blood flow. However, as angiogenesis is a complex process involving formation of 301 
abnormally dilated vessels and proliferation of microvessels, access to additional methods 302 
to non-invasively assess the size and density of tumor vessels can provide important 303 
additional information. To this end, an additional MR approach was developed to provide a 304 
more anatomical description of the tumor vessel network [22]. In this context, MR 305 
sequences are based on the ratio of gradient and spin echo relaxation rate changes 306 
(ΔR*2/ΔR2) after injection of an iron oxide-based superparamagnetic contrast agent of 307 
high molecular weight. ΔR2*/ΔR2 increases with increasing vessel size, allowing the 308 
calculation of average vessel size within a voxel. A good correlation has been demonstrated 309 
between MRI derived vessel size and density index and histology [13, 23]. 310 
In this study we sought to measure tumor vessel size and density using such dedicated 311 
sequences recently implemented by our group and others [12, 13]. Our approach facilitates 312 
the assessment of vessel parameters, total and microvessel tumor blood volume, VSI, and 313 
MDI from ΔR2*, ΔR2 and ADC maps. These MR sequences may be adapted for clinical 314 
translation [24]. We believe that providing anatomical information on tumor vasculature 315 
could complement the physiological information provided by DCE-MRI towards a more 316 
complete characterization of the tumor angiogenesis process. Unfortunately, due to 317 
practical (time) limitations during our experimental pre-clinical imaging procedures it was 318 
not feasible to include a DCE-MRI protocol. Furthermore, the effect of Gd injections on 319 
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VSOP T2/T2* relaxation is as of yet unknown, as is any effect of VSOP on putative DCE-320 
MRI T1 relaxation.  321 
Using T2w MRI, we have shown that treatment with BEV alone results in a pronounced 322 
decrease in tumor volume.  A similar finding has been observed in patients, with effects 323 
evident within two weeks of treatment [25]. However, our data suggests that BEV/BEZ235 324 
combination does not further decrease GBM tumor volume compared to BEV 325 
monotherapy. Thus, it is possible that there is redundancy in the pro-growth signaling 326 
pathways inhibited by both BEV and BEZ235.  These observations are supported by Ki67 327 
proliferation index and [18F]FLT uptake studies. [18F]FLT uptake has been shown to 328 
strongly correlate with tumor response following BEZ235 treatment in mouse models of 329 
gastric cancer [26] and anaplastic large cell lymphoma [27].  [18F]FLT has been used 330 
previously to evaluate response to BEV treatment e.g. in combination with irinotecan [28] 331 
and warrants continued assessment as a clinical imaging biomarker of response. 332 
Using ΔR2* and ΔR2 values respectively, we have shown that BEZ235 + BEV 333 
combination significantly reduces GBM tumor blood volume and tumor microvessel 334 
volume in comparison to BEV alone, likely due to BEZ235 mediated inhibition of tumor 335 
vessel signaling pathways. Most brain tumors over-secrete VEGF, which on binding and 336 
signaling though its receptor (VEGFR2) results in angiogenesis, vasculogeneis and 337 
abnormal permeabilisation of the tumor vasculature. This hyper-permeability allows fluid 338 
to leak from the intravascular space into the brain parenchyma, which causes vasogenic 339 
cerebral edema and increased interstitial fluid pressure.  Herein we, and elsewhere others 340 
[18], have shown that treatment with BEV (which inhibits VEGFA binding to its receptor) 341 
reduces GBM tumor vessel permeability.  It is possible that synergistic inhibition of 342 
VEGFA/VEGFR2 binding (BEV) alongside inhibition of the VEGFR2 downstream 343 
PI3K/mTOR pathway (BEZ235) may explain the enhanced reduction in tumor blood 344 
volume we observe following combinatorial therapy. 345 
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BEV has previously been shown to decrease tumor blood volume as measured using 346 
gadolinium-based DCE- MRI in a rat model of GBM [7]. Moreover high-grade glioma 347 
patients with low tumor blood volume following treatment with BEV, demonstrate 348 
improved progression free survival (PFS) compared to patients with high tumor blood 349 
volume [29].  We hypothesize that the effect of BEZ35/BEV combination could translate to 350 
improved quality of life for GBM patients by supporting reduced peritumoral edema [7, 351 
30].  352 
Data elucidating BEZ235/BEV effects on tumor blood volume and tumor micro-vessel 353 
volume are further supported by observed vessel density reduction in the combination 354 
group as measured by vWF staining. A corresponding trend towards decreased MDI was 355 
also observed in the combination group.  Further studies are warranted to fully unravel the 356 
utility of MDI as a novel anti-angiogenic imaging biomarker. 357 
We also assessed tumor uptake of the novel tracer [18F]FET PET to monitor therapy 358 
response. [18F]FET uptake is driven by large neutral amino acid transport and has been 359 
shown to correlate with L-type amino acid transporter expression (predominantly in the 360 
tumor cytoplasm and on the vascular endothelium), microvessel density and vessel 361 
formation in glioma [31]. [18F]FET uptake has further been evaluated clinically as a 362 
prognostic marker of BEV + irinotecan response and has been shown to perform better than 363 
Response Assessment in Neuro-Oncology (RANO) criteria towards prediction of treatment 364 
failure [32].  As before [32], we observed decreased [18F]FET uptake following BEV, but 365 
failed to observe further reduced [18F]FET uptake in the combination cohort. Nevertheless, 366 
as [18F]FET also accumulates in actively metabolizing tumor cells, this finding would 367 
further support our earlier observations  which suggest that the combination regimen fails 368 
to elicit enhanced direct tumor response.  369 
vWF IHC data suggests that mean tumor vessel size is increased in all treatment cohorts.  370 
These data agree with recent studies which showed increased tumor vessel size following 371 
BEV treatment in an orthotopic rat spheroid model, suggesting vessel normalization, 372 
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maturation and pruning of immature vessels following treatment [13]. Surprisingly, VSI 373 
data showed no effect in any treatment cohort.  IHC derived VSI values have previously 374 
been shown to correlate with VSI values derived using the imaging method described here 375 
[12]. However, this study did not assess VSI correlations post treatment with anti-376 
angiogenic agents. Further refinement of VSI as a robust imaging biomarker is required to 377 
decrease parameter variability.   378 
Herein, we have demonstrated the utility of implementing a multi-modality, multi 379 
parametric imaging approach towards the mechanistic interrogation of BEZ235/ BEV 380 
combination in a murine model of glioblastoma. Assessing novel MRI parameters (ΔR2*, 381 
ΔR2 and ADC maps to derive total and microvessel tumor blood volume, VSI and MDI) 382 
together with [18F]FET and [18F]FLT PET has informed drug mechanism of action and 383 
further provided clues to potential clinical response; The extensive pre-clinical imaging 384 
protocol employed  has thus provided important clues as to potential drug limitations  (vis a 385 
vis potential clinical efficacy) and/or putative benefits. It is possible that translation of a 386 
BEZ35/BEV combination regimen to the clinic could further reduce peritumoral edema, 387 
obviating the requirement for steroid treatment and improving patient quality of life. 388 
Additional pre-clinical studies using larger animal cohorts and clinically relevant orthotopic 389 
GBM patient derived xenograft models are warranted to extend on and validate these 390 
findings.  Nevertheless extensive studies of this kind performed in the pre-clinic are 391 
increasingly necessary to refine clinical trial design, to better define the clinical setting 392 
where experimental regimens are likely to succeed, and to avoid long and costly clinical 393 
studies which may ultimately fail due to lack of response or toxicities. Implementing 394 
mechanistic hypothesis driven pre-clinical molecular imaging biomarker studies facilitates 395 
robust interrogation of drug response. These data may more accurately predict the true 396 
clinical potential of novel therapeutic approaches.  397 
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Figure Legends  524 
Figure 1: Effect of BEZ235/BEV combination on GBM tumor volume and growth 525 
Post-treatment imaging and IHC analyses were performed following 3 weeks of treatment.  526 
(A) T2w MRI derived tumor volume.  (B) Representative trans-axial [18F]FLT PET images 527 
co-registered with MR in the same mouse. (C) Quantification of [18F]FLT uptake. (D, upper 528 
panel) Representative micrographs of Ki67 assessment of tumor cell proliferation (20x), 529 
(D, lower panel) Quantitation of proliferation index (Ki67 staining). * *P < 0.05, ** P < 530 
0.005, *** P < 0.001. Data points within each group represent individual tumors analyzed.   531 
 532 
Figure 2: Effect of BEZ235/ BEV combination on tumor blood volume and vasculature   533 
(A) Trans-axial co-registered brain image sections for a representative mouse.  (B) tumor 534 
blood volume and (C) microvessel blood volume,.  *P < 0.05.  Data points within groups 535 
represent individual tumors analyzed  536 
 537 
Figure 3: Effect of BEZ235/ BEV treatment on GBM vessel density and [18F]FET uptake 538 
(A) Representative trans-axial sections of  co-registered images (MDI) of a representative 539 
mouse. (B) Quantification of MDI in treatment cohorts. (C) Representative transaxial 540 
sections of [18F]FET  showing PET uptake co-registered with MR images in the same 541 
mouse. (D) Quantification of [18F]FET uptake.  (E, upper panel) vWF staining of tumor 542 
vessel density (20x). (E, lower panel)) Quantitation of vWF staining  *P < 0.05* Data 543 
points within groups represent individual tumors analyzed. 544 
 545 
Figure 4: Effect of BEZ235/ BEV treatment on tumor vessel size 546 
(A) Quantification of VSI in treatment cohorts. (B) vWF staining of tumor vessel size 547 
(20x). (C) Quantification of tumor vessel size by vWF staining *P < 0.05* Data points 548 
within groups represent individual tumors analyzed. 549 
 550 
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Supplementary Figure 1: Correlation of imaging and IHC data 551 
(A) Correlation of MDI with microvessel density as determined by vWF staining. (B) 552 
Correlation of [18F]FET uptake with microvessel density as determined by vWF staining.  553 
(C) Correlation of MDI with [18F]FET uptake. (D) Correlation of [18F]FLT uptake, with 554 
Ki67 index.   555 
